|
1
|
Paleiron N, Bylicki O, André M, Rivière E,
Grassin F, Robinet G and Chouaïd C: Targeted therapy for localized
non-small-cell lung cancer: A review. Onco Targets Ther.
9:4099–4104. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Whiteman DC and Wilson LF: The fractions
of cancer attributable to modifiable factors: A global review.
Cancer Epidemiol. 44:203–221. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hamilton G, Rath B and Ulsperger E: A
review of the role of surgery for small cell lung cancer and the
potential prognostic value of enumeration of circulating tumor
cells. Eur J Surg Oncol. 42:1296–1302. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kuribayashi K, Funaguchi N and Nakano T:
Chemotherapy for advanced non-small cell lung cancer with a focus
on squamous cell carcinoma. J Cancer Res Ther. 12:528–534. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Giaj-Levra N, Ricchetti F and Alongi F:
What is changing in radiotherapy for the treatment of locally
advanced nonsmall cell lung cancer patients? A review. Cancer
Invest. 34:80–93. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen L, He Z, Qin L, Li Q, Shi X, Zhao S,
Chen L, Zhong N and Chen X: Antitumor effect of malaria parasite
infection in a murine Lewis lung cancer model through induction of
innate and adaptive immunity. PLoS One. 6:e244072011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim JO, Jung SS, Kim SY, Kim TY, Shin DW,
Lee JH and Lee YH: Inhibition of Lewis lung carcinoma growth by
Toxoplasma gondii through induction of Th1 immune responses and
inhibition of angiogenesis. J Korean Med Sci. 22:(Suppl). S38–S46.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Martínez A, Torello S and Kolter R:
Sliding motility in mycobacteria. J Bacteriol. 181:7331–7338.
1999.PubMed/NCBI
|
|
9
|
Garg A, Barnes PF, Roy S, Quiroga MF, Wu
S, García VE, Krutzik SR, Weis SE and Vankayalapati R:
Mannose-capped lipoarabinomannan- and prostaglandin E2-dependent
expansion of regulatory T cells in human Mycobacterium
tuberculosis infection. Eur J Immunol. 38:459–469. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gehring AJ, Rojas RE, Canaday DH, Lakey
DL, Harding CV and Boom WH: The Mycobacterium tuberculosis
19-kilodalton lipoprotein inhibits gamma interferon-regulated
HLA-DR and Fc gamma R1 on human macrophages through Toll-like
receptor 2. Infect Immun. 71:4487–4497. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu H, Komai-Koma M, Xu D and Liew FY:
Toll-like receptor 2 signaling modulates the functions of
CD4+ CD25+ regulatory T cells. Proc Natl Acad
Sci USA. 103:7048–7053. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hirsch CS, Rojas R, Wu M and Toossi Z:
Mycobacterium tuberculosis induces expansion of Foxp3
positive CD4 T-cells with a regulatory profile in tuberculin
non-sensitized healthy subjects: Implications for effective
immunization against TB. J Clin Cell Immunol. 7:72016. View Article : Google Scholar
|
|
13
|
He XY, Xiao L, Chen HB, Hao J, Li J, Wang
YJ, He K, Gao Y and Shi BY: T regulatory cells and Th1/Th2
cytokines in peripheral blood from tuberculosis patients. Eur J
Clin Microbiol Infect Dis. 29:643–650. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kuo CH, Lo CY, Chung FT, Lee KY, Lin SM,
Wang CH, Heh CC, Chen HC and Kuo HP: Concomitant active
tuberculosis prolongs survival in non-small cell lung cancer: A
study in a tuberculosis-endemic country. PLoS One. 7:e332262012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen C, Liu Y, Liu Y and Zheng P: mTOR
regulation and therapeutic rejuvenation of aging hematopoietic stem
cells. Sci Signal. 2:ra752009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhou H, Wang Y, Lian Q, Yang B, Ma Y, Wu
X, Sun S, Liu Y and Sun B: Differential IL-10 production by DCs
determines the distinct adjuvant effects of LPS and PTX in EAE
induction. Eur J Immunol. 44:1352–1362. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu C, Fillmore CM, Koyama S, Wu H, Zhao Y,
Chen Z, Herter-Sprie GS, Akbay EA, Tchaicha JH, Altabef A, et al:
Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with
elevated PD-L1 expression. Cancer Cell. 25:590–604. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zamarron BF and Chen W: Dual roles of
immune cells and their factors in cancer development and
progression. Int J Biol Sci. 7:651–658. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wieder T, Braumüller H, Kneilling M,
Pichler B and Röcken M: T cell-mediated help against tumors. Cell
Cycle. 7:2974–2977. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sakaguchi S, Miyara M, Costantino CM and
Hafler DA: FOXP3+ regulatory T cells in the human immune
system. Nat Rev Immunol. 10:490–500. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Maynard CL, Hatton RD, Helms WS, Oliver
JR, Stephensen CB and Weaver CT: Contrasting roles for all-trans
retinoic acid in TGF-beta-mediated induction of Foxp3 and Il10
genes in developing regulatory T cells. J Exp Med. 206:343–357.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Roychoudhuri R, Eil RL and Restifo NP: The
interplay of effector and regulatory T cells in cancer. Curr Opin
Immunol. 33:101–111. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yasumoto K, Hanagiri T and Takenoyama M:
Lung cancer-associated tumor antigens and the present status of
immunotherapy against non-small-cell lung cancer. Gen Thorac
Cardiovasc Surg. 57:449–457. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Alexandroff AB, Jackson AM, O'Donnell MA
and James K: BCG immunotherapy of bladder cancer: 20 years on.
Lancet. 353:1689–1694. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hibbs JB Jr, Lambert LH Jr and Remington
JS: Resistance to murine tumors conferred by chronic infection with
intracellular protozoa, Toxoplasma gondii and Besnoitia jellisoni.
J Infect Dis. 124:587–592. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Grange JM, Bottasso O, Stanford CA and
Stanford JL: The use of mycobacterial adjuvant-based agents for
immunotherapy of cancer. Vaccine. 26:4984–4990. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Malmström PU, Wijkström H, Lundholm C,
Wester K, Busch C and Norlén BJ: Swedish-Norwegian Bladder Cancer
Study Group: 5-year followup of a randomized prospective study
comparing mitomycin C and bacillus Calmette-Guerin in patients with
superficial bladder carcinoma. J Urol. 161:1124–1127. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Stanford JL, Stanford CA, O'Brien ME and
Grange JM: Successful immunotherapy with Mycobacterium
vaccae in the treatment of adenocarcinoma of the lung. Eur J
Cancer. 44:224–227. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ordway D, Henao-Tamayo M, Harton M,
Palanisamy G, Troudt J, Shanley C, Basaraba RJ and Orme IM: The
hypervirulent Mycobacterium tuberculosis strain HN878
induces a potent TH1 response followed by rapid down-regulation. J
Immunol. 179:522–531. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Scott-Browne JP, Shafiani S, Tucker-Heard
G, Ishida-Tsubota K, Fontenot JD, Rudensky AY, Bevan MJ and Urdahl
KB: Expansion and function of Foxp3-expressing T regulatory cells
during tuberculosis. J Exp Med. 204:2159–2169. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Trinath J, Maddur MS, Kaveri SV, Balaji KN
and Bayry J: Mycobacterium tuberculosis promotes regulatory
T-cell expansion via induction of programmed death-1 ligand 1
(PD-L1, CD274) on dendritic cells. J Infect Dis. 205:694–696. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Periasamy S, Dhiman R, Barnes PF,
Paidipally P, Tvinnereim A, Bandaru A, Valluri VL and Vankayalapati
R: Programmed death 1 and cytokine inducible SH2-containing protein
dependent expansion of regulatory T cells upon stimulation With
Mycobacterium tuberculosis. J Infect Dis. 203:1256–1263.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Alvarez IB, Pasquinelli V, Jurado JO,
Abbate E, Musella RM, de la Barrera SS and García VE: Role played
by the programmed death-1-programmed death ligand pathway during
innate immunity against Mycobacterium tuberculosis. J Infect
Dis. 202:524–532. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li L, Lao SH and Wu CY: Increased
frequency of CD4(+)CD25(high) Treg cells inhibit BCG-specific
induction of IFN-gamma by CD4(+) T cells from TB patients.
Tuberculosis (Edinb). 87:526–534. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Francisco LM, Salinas VH, Brown KE,
Vanguri VK, Freeman GJ, Kuchroo VK and Sharpe AH: PD-L1 regulates
the development, maintenance, and function of induced regulatory T
cells. J Exp Med. 206:3015–3029. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jiang X, Zhou J, Giobbie-Hurder A, Wargo J
and Hodi FS: The activation of MAPK in melanoma cells resistant to
BRAF inhibition promotes PD-L1 expression that is reversible by MEK
and PI3K inhibition. Clin Cancer Res. 19:598–609. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang C, Yi T, Qin L, Maldonado RA, von
Andrian UH, Kulkarni S, Tellides G and Pober JS: Rapamycin-treated
human endothelial cells preferentially activate allogeneic
regulatory T cells. J Clin Invest. 123:1677–1693. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lastwika KJ, Wilson W III, Li QK, Norris
J, Xu H, Ghazarian SR, Kitagawa H, Kawabata S, Taube JM, Yao S, et
al: Control of PD-L1 expression by oncogenic activation of the
AKT-mTOR pathway in non-small cell lung cancer. Cancer Res.
76:227–238. 2016. View Article : Google Scholar : PubMed/NCBI
|
